Cart
sales@molnova.com
DMU2139
CAS No. 104890-70-2
DMU2139( —— )
Catalog No. M22628 CAS No. 104890-70-2
DMU2139 is a specific CYP1B1 inhibitor (CYP1B1 and CYP1A1 with IC50 of 9 nM and 795 nM, respectively).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 69 | In Stock |
|
| 5MG | 69 | In Stock |
|
| 10MG | 112 | In Stock |
|
| 25MG | 226 | In Stock |
|
| 50MG | 327 | In Stock |
|
| 100MG | 486 | In Stock |
|
| 200MG | 704 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameDMU2139
-
NoteResearch use only, not for human use.
-
Brief DescriptionDMU2139 is a specific CYP1B1 inhibitor (CYP1B1 and CYP1A1 with IC50 of 9 nM and 795 nM, respectively).
-
DescriptionDMU2139 is a specific CYP1B1 inhibitor (CYP1B1 and CYP1A1 with IC50 of 9 nM and 795 nM, respectively).
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayMetabolic Enzyme/Protease
-
TargetP450
-
RecptorCYP1B1
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number104890-70-2
-
Formula Weight289.3
-
Molecular FormulaC19H15NO2
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESCOc1ccc2cc(ccc2c1)C(=O)\C=C\c1cccnc1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Horley N J , Beresford K J M , Chawla T , et al. Discovery and characterization of novel CYP1B1 inhibitors based on heterocyclic chalcones: Overcoming cisplatin resistance in CYP1B1-overexpressing lines[J]. European Journal of Medicinal Chemistry, 2017, 129:159-174.
molnova catalog
related products
-
Liarozole
Liarozole is a cytochrome P450 (CYP450) dependent inhibitor, orally active, it also a potent inhibitor of estrogen (via inhibition of aromatase) and testicular androgen synthesis (inhibition of 17 ,20-lyase).
-
7-Hydroxyflavone
7-Hydroxyflavone is a potent inhibitor of CYP1A1 with a Ki value of 0.015 μM and exhibits 6-fold greater selectivity for CYP1A1 over CYP1A2.with anti-inflammatory activity.
-
Enerisant HCl
Enerisant HCl is a novel potent and selective histamine H3 receptor antagonist, a substrate for P-gp, mediated by cytochrome P450 (CYP) and transporter proteins.
